An announcement from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics Corp., has filed its unaudited condensed interim consolidated financial statements for the three and six months ended January 31, 2025, with relevant Canadian securities commissions. The financial statements reveal a continued operating loss, with a total comprehensive loss of $233,185 for the six-month period, indicating ongoing financial challenges for the company.
More about BriaCell Therapeutics
YTD Price Performance: -56.21%
Average Trading Volume: 11,332
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$19.73M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.